← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › I.V. SOLUTION ADDITIVES › Electrolyte solutions
magnesium phosphate
B05XA10
Forms & Strengths
- Injectable solution: 0.5 mEq/mL magnesium and 0.5 mEq/mL phosphate
- Oral supplements (various combination formulations)
Adult Dosing
- Mild hypomagnesemia/hypophosphatemia: Oral doses vary based on specific salt content and clinical guidelines
- Severe deficiency: IV administration guided by serum magnesium and phosphate levels, typically not exceeding 8-12 mEq magnesium per 24 hours in divided doses
Pediatric Dosing
- Safety and efficacy in pediatric patients not well established; individualize dosage based on serum electrolyte monitoring and clinical status
Indications
- Prevention and treatment of magnesium deficiency
- Prevention and treatment of hypophosphatemia
- Correction of electrolyte imbalances associated with parenteral nutrition or chronic malabsorption
Mechanism of Action
- Magnesium is an essential cofactor for numerous enzymatic reactions, regulates neuromuscular excitability, and maintains vascular tone
- Phosphate is a vital intracellular anion required for energy storage (ATP), nucleic acid synthesis, and buffering systems
Contraindications
- Myasthenia gravis
- Severe renal impairment (creatinine clearance < 30 mL/min)
- Hypermagnesemia
- Hyperphosphatemia
- Heart block or myocardial damage
Adverse Reactions
- Hypotension
- Flushing
- Sweating
- Nausea and diarrhea (oral administration)
- Muscle weakness
- Respiratory depression (in severe hypermagnesemia)
- Bradycardia and cardiac arrhythmias
Drug Interactions
- Neuromuscular blockers: Enhanced neuromuscular blockade
- Digitalis glycosides: Increased risk of cardiac arrhythmias
- Aminoglycosides and other nephrotoxic drugs: Increased risk of toxicity
- Oral tetracyclines and fluoroquinolones: Reduced absorption of the antibiotic due to chelation
Curated Content: Needs Vetting Before Put to Clinical Use